• 1
    Moulder JE, Rockwell S. Hypoxic fractions of solid tumors: experimental techniques, methods of analysis, and surveys of existing data. Int J Radiat Oncol Biol Phys. 1984; 10: 695712.
  • 2
    Teicher BA, Holden SA, Al-Achi A, Herman TS. Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in-vivo in the FSaIIC murine fibrosarcoma. Cancer Res. 1990; 50: 33393344.
  • 3
    Brizel DM, Dodge RK, Clough RW, Dewhirst MW. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother Oncol. 1999; 53: 113117.
  • 4
    Nordsmark M, Overgaard J. A confirmatory prognostic study on oxygenation status and loco-regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy. Radiother Oncol. 2000; 57: 3943.
  • 5
    Rudat V, Vanselow B, Wollensack P, et al. Repeatability and prognostic impact of the pretreatment pO(2) histography in patients with advanced head and neck cancer. Radiother Oncol. 2000; 57: 3137.
  • 6
    Peters KB, Brown JM. Tirapazamine: a hypoxia-activated topoisomerase II poison. Cancer Res. 2002; 62: 52485253.
  • 7
    Brown JM. SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumors. Br J Cancer. 1993; 67: 11631170.
  • 8
    Brown JM, Lemmon MJ. Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Res. 1990; 50: 77457749.
  • 9
    Dorie MJ, Brown JM. Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin. Cancer Res. 1993; 53: 46334636.
  • 10
    Dorie MJ, Brown JM. Modification of the antitumor activity of chemotherapeutic drugs by the hypoxic cytotoxic agent tirapazamine. Cancer Chemother Pharmacol. 1997; 39: 361366.
  • 11
    Lee DJ, Trotti A, Spencer S, et al. Concurrent tirapazamine and radiotherapy for advanced head and neck carcinomas: a Phase II study. Int J Radiat Oncol Biol Phys. 1998; 42: 811815.
  • 12
    Rischin D, Peters L, Hicks R, et al. Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. J Clin Oncol. 2001; 19: 535542.
  • 13
    Rischin D, Peters L, Fisher R, et al. Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: a randomized Phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). J Clin Oncol. 2005; 23: 7987.
  • 14
    Pinto HA, Le QT, Terris DJ, Bloch D, Goffinet DR, Brown JM, Randomized trial of tirapazamine/cisplatin/fluorouracil versus cisplatin/fluorouracil for organ preservation in advanced resectable head and neck cancer (abstract 904). Proc Am Soc Clin Oncol. 2002; 21: 227a.
  • 15
    Terris DJ, Dunphy EP. Oxygen tension measurements of head and neck cancers. Arch Otolaryngol Head Neck Surg. 1994; 120: 283287.
  • 16
    Olive PL. Use of the comet assay to detect hypoxic cells in murine tumours and normal tissues exposed to bioreductive drugs. Acta Oncol. 1995; 34: 301305.
  • 17
    Dorie MJ, Kovacs MS, Gabalski EC, et al. DNA damage measured by the comet assay in head and neck cancer patients treated with tirapazamine. Neoplasia. 1999; 1: 461467.
  • 18
    Le QT, Kovacs MS, Dorie MJ, et al. Comparison of the comet assay and the oxygen microelectrode for measuring tumor oxygenation in head-and-neck cancer patients. Int J Radiat Oncol Biol Phys. 2003; 56: 375383.
  • 19
    Star-Lack J, Spielman D, Adalsteinsson E, Kurhanewicz J, Terris DJ, Vigneron DB. In vivo lactate editing with simultaneous detection of choline, creatine, NAA, and lipid singlets at 1.5 T using PRESS excitation with applications to the study of brain and head and neck tumors. J Magn Reson. 1998; 133: 243254.
  • 20
    von Pawel J, von Roemeling R, Gatzemeier U, et al. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: a report of the International CATAPULT I Study Group. Cisplatin and tirapazamine in subjects with advanced previously untreated non-small-cell lung tumors. J Clin Oncol. 2000; 18: 13511359.
  • 21
    Shulman LN, Boswell L, Riese N, et al. Phase I trial of the hypoxic cell cytotoxin tirapazamine with concurrent radiation therapy in the treatment of refractory solid tumors. Int J Radiat Oncol Biol Phys. 1999; 44: 349353.
  • 22
    National Cancer Institute. Common toxicity criteria. Available at URL: [accessed December 2003].
  • 23
    Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995; 31: 13411346.
  • 24
    Kaplan ES, Meier P. Non-parametric estimations from incomplete observations. J Am Stat Assoc. 1958; 53: 457482.
  • 25
    Cox DR. Regression models and life tables. J R Stat Soc. 1972; 34: 187220.
  • 26
    Gray LH, Conger AD, Ebert M, Hornsey S, Scott OC. Concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol. 1953; 26: 638648.
  • 27
    Eschwege F, Sancho-Garnier H, Chassagne D, et al. Results of a European randomized trial of etanidazole combined with radiotherapy in head and neck carcinomas [see comments]. Int J Radiat Oncol Biol Phys. 1997; 39: 275281.
  • 28
    Lee DJ, Cosmatos D, Marcial VA, et al. Results of an RTOG Phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas [see comments]. Int J Radiat Oncol Biol Phys. 1995; 32: 56776.
  • 29
    Overgaard J, Hansen HS, Anderson AP, et al. Misonidazole combined with split course radiotherapy in the treatment of invasive carcinoma of larynx and pharynx: report from the DAHANCA study. Int J Radiat Oncol Biol Phys. 1989; 16: 10651068.
  • 30
    Fazekas JT, Pajak TF, Wasserman T, et al. Failure of misonidazole-sensitized radiotherapy to impact upon outcome among Stage III-IV squamous cancers of the head and neck. Int J Radiat Oncol Biol Phys. 1987; 13: 11551160.
  • 31
    Chao KS. Protection of salivary function by intensity-modulated radiation therapy in patients with head and neck cancer. Semin Radiat Oncol. 2002; 12(1 Suppl 1 ): 2025.
  • 32
    Lee N, Xia P, Fischbein NJ, Akazawa P, Akazawa C, Quivey JM. Intensity-modulated radiation therapy for head-and-neck cancer: the UCSF experience focusing on target volume delineation. Int J Radiat Oncol Biol Phys. 2003; 57: 4960.
  • 33
    Brizel DM, Wasserman TH, Henke M, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol. 2000; 18: 33393345.